Sideris Pharmaceuticals is a biopharmaceutical company focused on the development of new treatments for transfusion related iron overload

Sideris’ lead clinical candidate, SP-420, is designed to be a best-in-class oral iron chelator.

We are advancing SP-420 on a well-defined clinical development path to meet the significant medical need for improved iron chelation medicines.

News:

January 7, 2014, Sideris Pharmaceuticals Appoints Gregory I. Berk, M.D., as President and Chief Medical Officer

October 22, 2013, Sideris Completes $32M Equity Financing and Signs Agreement with Global Pharmaceutical Company.